Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

From new leadership and expansions, here are five key updates from spine and orthopedic devicemakers since Sept. 11.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of Medtronic PLC climbed toward a three-month high in early Tuesday trading, after the medical-technology company topped fiscal first-quarter earnings expectations, amid strength in its ...

A month has gone by since the last earnings report for Medtronic (MDT). Shares have added about 0.7 ... namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes ...

The company operates in four business segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Medtronic sells products in many end markets in these segments. It is usually the ...

Aug 20 (Reuters) - Medtronic (MDT.N), opens new tab slightly ... posted a revenue beat across segments except for its medical surgical unit, which was affected by a slowdown in the Korean market ...

Objectives Modern advances in bioprosthetic valve tissue technology have resulted in the development of newer generation bioprosthetic aortic valves such as the Edwards Lifesciences® Inspiris Resilia ...

Medtronic's business is diversified. The company boasts dozens of devices across four main segments: Medical surgical, neuroscience, cardiovascular, and diabetes. Though Medtronic records ...

Medtronic Plc is a medical technology company ... Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for ...